Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Retinoblastoma 3Stomach Neoplasms 2Pancreatic Neoplasms 2Keratosis, Actinic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinal Neoplasms 1Rectal Neoplasms 1Peripheral Nervous System Diseases 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Neoplasms 1Condylomata Acuminata 1Colorectal Neoplasms 1Colonic Neoplasms 1Appendiceal Neoplasms 1

Interventions

Rituximab 208Cyclophosphamide 167Etoposide 83Prednisone 79Vincristine 77Doxorubicin 76Peripheral Blood Stem Cell Transplantation 61Filgrastim 55Cytarabine 47fludarabine phosphate 46Radiotherapy 43Lenalidomide 41Mycophenolic Acid 40Tacrolimus 36Methotrexate 35Melphalan 35Busulfan 35Gemcitabine 32Carmustine 32Cyclosporine 31Whole-Body Irradiation 29Ifosfamide 28Antilymphocyte Serum 26zanubrutinib 25polatuzumab vedotin 25Dexamethasone 23Methylprednisolone 22ibritumomab tiuxetan 20Carboplatin 20Oxaliplatin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large B-Cell, Diffuse × Cryotherapy × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡